## We claim

1. Compounds of the general formulas (I-A) and (I-B)

wherein

5

10

15

20

A represents an aryl or heteroaryl ring,

R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> independently from each other represent hydrogen, halogen, nitro, cyano, C<sub>1</sub>-C<sub>6</sub>-alkyl, hydroxy or C<sub>1</sub>-C<sub>6</sub>-alkoxy, wherein C<sub>1</sub>-C<sub>6</sub>-alkyl and C<sub>1</sub>-C<sub>6</sub>-alkoxy can be further substituted with one to three identical or different radicals selected from the group consisting of halogen, hydroxy and C<sub>1</sub>-C<sub>4</sub>-alkoxy,

R<sup>4</sup> represents C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>1</sub>-C<sub>6</sub>-alkylcarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkoxycarbonyl, hydroxycarbonyl, aminocarbonyl, mono- or di-C<sub>1</sub>-C<sub>4</sub>-alkylaminocarbonyl, C<sub>6</sub>-C<sub>10</sub>-arylaminocarbonyl, heteroarylcarbonyl, heterocyclylcarbonyl, heteroaryl, heterocyclyl or cyano, wherein C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>1</sub>-C<sub>6</sub>-alkylcarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkoxycarbonyl, mono- and di-C<sub>1</sub>-C<sub>4</sub>-alkylaminocarbonyl can be further substituted with one to three identical or different radicals selected from the group consisting of C<sub>3</sub>-C<sub>8</sub>-cycloalkyl, hydroxy, C<sub>1</sub>-C<sub>4</sub>-alkoxy, C<sub>1</sub>-C<sub>4</sub>-alkoxycarbonyl,

R<sup>5</sup>

hydroxycarbonyl, aminocarbonyl, mono- and di- $C_1$ - $C_4$ -alkylamino-carbonyl,  $C_1$ - $C_4$ -alkylcarbonylamino, amino, mono- and di- $C_1$ - $C_4$ -alkylamino, heteroxyl, heteroxylyl, tri- $(C_1$ - $C_6$ -alkyl)-silyl and cyano,

5

represents C<sub>1</sub>-C<sub>4</sub>-alkyl, which can be substituted with one to three identical or different radicals selected from the group consisting of halogen, hydroxy, C<sub>1</sub>-C<sub>6</sub>-alkoxy, C<sub>2</sub>-C<sub>6</sub>-alkenoxy, C<sub>1</sub>-C<sub>6</sub>-alkylthio, amino, mono- and di-C<sub>1</sub>-C<sub>6</sub>-alkylamino, arylamino, hydroxycarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkoxycarbonyl and the radical -O-C<sub>1</sub>-C<sub>4</sub>-alkyl-O-C<sub>1</sub>-C<sub>4</sub>-alkyl,

10

R<sup>6A</sup> represents hydrogen, C<sub>1</sub>-C<sub>6</sub>-alkylcarbonyl, C<sub>3</sub>-C<sub>8</sub>-cycloalkylcarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkoxycarbonyl, mono- or di-C<sub>1</sub>-C<sub>4</sub>-alkylaminocarbonyl, wherein C<sub>1</sub>-C<sub>6</sub>-alkylcarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkoxycarbonyl, mono- and di-C<sub>1</sub>-C<sub>4</sub>-alkylaminocarbonyl can be substituted with one to three identical or different radicals selected from the group consisting of C<sub>3</sub>-C<sub>8</sub>-cycloalkyl, hydroxy, C<sub>1</sub>-C<sub>4</sub>-alkoxy, amino, mono- and di-C<sub>1</sub>-C<sub>4</sub>-alkylamino,

15

20

R<sup>6B</sup> represents C<sub>1</sub>-C<sub>6</sub>-alkyl, which can be substituted with one to three identical or different radicals selected from the group consisting of hydroxy, C<sub>1</sub>-C<sub>4</sub>-alkoxy, amino, mono- and di-C<sub>1</sub>-C<sub>4</sub>-alkylamino, C<sub>1</sub>-C<sub>4</sub>-alkoxycarbonyl, hydroxycarbonyl, aminocarbonyl, mono- and di-C<sub>1</sub>-C<sub>4</sub>-alkylaminocarbonyl, C<sub>1</sub>-C<sub>4</sub>-alkylcarbonyloxy, aminocarbonyloxy, cyano, aryl, heteroaryl and heterocyclyl, wherein heteroaryl and heterocyclyl can be further substituted with one to two identical or different radicals selected from the group consisting of C<sub>1</sub>-C<sub>4</sub>-alkyl, hydroxy and oxo,

25

R<sup>7</sup> represents halogen, nitro, cyano, C<sub>1</sub>-C<sub>6</sub>-alkyl, hydroxy or C<sub>1</sub>-C<sub>6</sub>-alkoxy, wherein C<sub>1</sub>-C<sub>6</sub>-alkyl and C<sub>1</sub>-C<sub>6</sub>-alkoxy can be further sub-

WO 2004/024701 PCT/EP2003/009527

stituted with one to three identical or different radicals selected from the group consisting of halogen, hydroxy and C<sub>1</sub>-C<sub>4</sub>-alkoxy,

and

5

15

20

25

- Y<sup>1</sup>, Y<sup>2</sup>, Y<sup>3</sup> and Y<sup>4</sup> independently from each other represent CH or N, wherein the ring contains either 0, 1 or 2 nitrogen atoms.
- 2. Compounds of general formulas (I-A) and (I-B) according to Claim 1,
  wherein
  - A represents an aryl or heteroaryl ring,
  - R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> independently from each other represent hydrogen, halogen, nitro, cyano, C<sub>1</sub>-C<sub>6</sub>-alkyl, hydroxy or C<sub>1</sub>-C<sub>6</sub>-alkoxy, wherein C<sub>1</sub>-C<sub>6</sub>-alkyl and C<sub>1</sub>-C<sub>6</sub>-alkoxy can be further substituted with one to three identical or different radicals selected from the group consisting of halogen, hydroxy and C<sub>1</sub>-C<sub>4</sub>-alkoxy,
  - R<sup>4</sup> represents C<sub>1</sub>-C<sub>6</sub>-alkylcarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkoxycarbonyl, hydroxycarbonyl, aminocarbonyl, mono- or di-C<sub>1</sub>-C<sub>4</sub>-alkylaminocarbonyl, C<sub>6</sub>-C<sub>10</sub>-arylaminocarbonyl, heteroarylcarbonyl, heterocyclylcarbonyl, heteroaryl, heterocyclyl or cyano, wherein C<sub>1</sub>-C<sub>6</sub>-alkylcarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkoxycarbonyl, mono- and di-C<sub>1</sub>-C<sub>4</sub>-alkylaminocarbonyl can be further substituted with one to three identical or different radicals selected from the group consisting of C<sub>3</sub>-C<sub>8</sub>-cycloalkyl, hydroxy, C<sub>1</sub>-C<sub>4</sub>-alkoxy, C<sub>1</sub>-C<sub>4</sub>-alkoxycarbonyl, hydroxycarbonyl, aminocarbonyl, mono- and di-C<sub>1</sub>-C<sub>4</sub>-alkylaminocarbonyl, C<sub>1</sub>-C<sub>4</sub>-alkylcarbonylamino, amino, mono- and di-C<sub>1</sub>-C<sub>4</sub>-alkylamino, heteroaryl, heterocyclyl and tri-(C<sub>1</sub>-C<sub>6</sub>-alkyl)-silyl,

- $\mathbb{R}^5$ represents C<sub>1</sub>-C<sub>4</sub>-alkyl, which can be substituted with one to three identical or different radicals selected from the group consisting of halogen, hydroxy, C<sub>1</sub>-C<sub>6</sub>-alkoxy, C<sub>2</sub>-C<sub>6</sub>-alkenoxy, C<sub>1</sub>-C<sub>6</sub>-alkylthio, amino, mono- and di-C<sub>1</sub>-C<sub>6</sub>-alkylamino, arylamino, hydroxycarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkoxycarbonyl and the radical -O-C<sub>1</sub>-C<sub>4</sub>-alkyl-O-C<sub>1</sub>-C<sub>4</sub>-alkyl,
- $R^{6A}$ represents hydrogen, C<sub>1</sub>-C<sub>6</sub>-alkylcarbonyl, C<sub>3</sub>-C<sub>8</sub>-cycloalkylcarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkoxycarbonyl, monodi-C<sub>1</sub>-C<sub>4</sub>-alkylaminocarbonyl, or wherein C<sub>1</sub>-C<sub>6</sub>-alkylcarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkoxycarbonyl, mono- and di-C<sub>1</sub>-C<sub>4</sub>-alkylaminocarbonyl can be substituted with one to three identi-10 cal or different radicals selected from the group consisting of C<sub>3</sub>-C<sub>8</sub>cycloalkyl, hydroxy, C<sub>1</sub>-C<sub>4</sub>-alkoxy, amino, mono- and di-C<sub>1</sub>-C<sub>4</sub>alkylamino,
- R<sup>6B</sup> represents C<sub>1</sub>-C<sub>6</sub>-alkyl, which can be substituted with one to three 15 identical or different radicals selected from the group consisting of hydroxy, C<sub>1</sub>-C<sub>4</sub>-alkoxy, amino, mono- and di-C<sub>1</sub>-C<sub>4</sub>-alkylamino, aryl, heteroaryl and heterocyclyl,
- $R^7$ 20 represents halogen, nitro, cyano, C<sub>1</sub>-C<sub>6</sub>-alkyl, hydroxy or C<sub>1</sub>-C<sub>6</sub>alkoxy, wherein  $C_1$ - $C_6$ -alkyl and  $C_1$ - $C_6$ -alkoxy can be further substituted with one to three identical or different radicals selected from the group consisting of halogen, hydroxy and C<sub>1</sub>-C<sub>4</sub>-alkoxy,
- 25 and

- Y<sup>1</sup>, Y<sup>2</sup>, Y<sup>3</sup> and Y<sup>4</sup> independently from each other represent CH or N, wherein the ring contains either 0, 1 or 2 nitrogen atoms.
- Compounds of general formulas (I-A) and (I-B) according to Claim 1 or 2, 30 3. wherein

10

15

20

25

30

and

- A represents a phenyl or pyridyl ring,
- R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> independently from each other represent hydrogen, fluoro, chloro, bromo, nitro, cyano, methyl, ethyl, trifluoromethyl or trifluoromethoxy,
- R<sup>4</sup> represents C<sub>1</sub>-C<sub>6</sub>-alkylcarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkoxycarbonyl, hydroxycarbonyl, aminocarbonyl, mono- or di-C<sub>1</sub>-C<sub>4</sub>-alkylaminocarbonyl or cyano, wherein C<sub>1</sub>-C<sub>6</sub>-alkylcarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkoxycarbonyl and mono-C<sub>1</sub>-C<sub>4</sub>-alkylaminocarbonyl can be substituted with one to three identical or different radicals selected from the group consisting of C<sub>3</sub>-C<sub>6</sub>-cycloalkyl, hydroxy, C<sub>1</sub>-C<sub>4</sub>-alkoxy, C<sub>1</sub>-C<sub>4</sub>-alkoxycarbonyl, amino, mono- or di-C<sub>1</sub>-C<sub>4</sub>-alkylamino, heteroaryl and heterocyclyl,
- R<sup>5</sup> represents methyl or ethyl,
- R<sup>6A</sup> represents hydrogen, C<sub>1</sub>-C<sub>6</sub>-alkylcarbonyl or C<sub>3</sub>-C<sub>6</sub>-cycloalkylcarbonyl, wherein C<sub>1</sub>-C<sub>6</sub>-alkylcarbonyl can be substituted with a radical selected from the group consisting of C<sub>3</sub>-C<sub>6</sub>-cycloalkyl, hydroxy, C<sub>1</sub>-C<sub>4</sub>-alkoxy, amino, mono- and di-C<sub>1</sub>-C<sub>4</sub>-alkylamino,
- R<sup>6B</sup> represents C<sub>1</sub>-C<sub>6</sub>-alkyl, which can be substituted with a radical selected from the group consisting of hydroxy, C<sub>1</sub>-C<sub>4</sub>-alkoxy, amino, mono- and di-C<sub>1</sub>-C<sub>4</sub>-alkylamino, phenyl, heteroaryl and heterocyclyl,
- R<sup>7</sup> represents halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, methyl or ethyl,

15

20

25

30

Y<sup>1</sup>, Y<sup>2</sup>, Y<sup>3</sup> and Y<sup>4</sup> each represent CH.

4. Compounds of general formulas (I-A) and (I-B) according to Claim 1, 2 or 3, wherein

A represents a phenyl or a pyridyl ring,

R<sup>1</sup> and R<sup>3</sup> each represent hydrogen,

- 10 R<sup>2</sup> represents fluoro, chloro, bromo, nitro or cyano,
  - R<sup>4</sup> represents C<sub>1</sub>-C<sub>4</sub>-alkylcarbonyl or C<sub>1</sub>-C<sub>4</sub>-alkoxycarbonyl, wherein C<sub>1</sub>-C<sub>4</sub>-alkoxycarbonyl can be substituted with a radical selected from the group consisting of hydroxy, C<sub>1</sub>-C<sub>4</sub>-alkoxy, C<sub>1</sub>-C<sub>4</sub>-alkoxycarbonyl, mono- and di-C<sub>1</sub>-C<sub>4</sub>-alkylamino, heteroaryl and heterocyclyl,
  - R<sup>5</sup> represents methyl,
  - R<sup>6A</sup> represents hydrogen, C<sub>1</sub>-C<sub>6</sub>-alkylcarbonyl or C<sub>3</sub>-C<sub>6</sub>-cycloalkyl-carbonyl,
    - R<sup>6B</sup> represents C<sub>1</sub>-C<sub>4</sub>-alkyl, which can be substituted with a radical selected from the group consisting of hydroxy, C<sub>1</sub>-C<sub>4</sub>-alkoxy, amino, di-C<sub>1</sub>-C<sub>4</sub>-alkylamino, phenyl, pyridyl, imidazolyl, pyrrolidino and morpholino,
    - R<sup>7</sup> represents trifluoromethyl or nitro,

and

 $Y^1$ ,  $Y^2$ ,  $Y^3$  and  $Y^4$  each represent CH.

- 5. Compounds of general formulas (I-A) and (I-B) according to at least one of Claims 1 to 4, wherein A is phenyl or pyridyl.
- 5 6. Compounds of general formulas (I-A) and (I-B) according to at least one of Claims 1 to 5, wherein R<sup>1</sup> is hydrogen.

- 7. Compounds of general formulas (I-A) and (I-B) according to at least one of Claims 1 to 6, wherein R<sup>2</sup> is cyano.
- 8. Compounds of general formulas (I-A) and (I-B) according to at least one of Claims 1 to 7, wherein R<sup>3</sup> is hydrogen.
- 9. Compounds of general formulas (I-A) and (I-B) according to at least one of Claims 1 to 8, wherein R<sup>4</sup> is C<sub>1</sub>-C<sub>4</sub>-alkoxycarbonyl, which can be substituted with dimethylamino, diethylamino, N-ethylmethylamino, pyrrolidino or piperidino, or wherein R<sup>4</sup> is C<sub>1</sub>-C<sub>4</sub>-alkylcarbonyl.
- 10. Compounds of general formulas (I-A) and (I-B) according to at least one of Claims 1 to 9, wherein R<sup>5</sup> is methyl.
  - 11. Compounds of general formulas (I-A) and (I-B) according to at least one of Claims 1 to 10, wherein R<sup>7</sup> is trifluoromethyl or nitro.
- 25 12. Compounds of general formula (I-A) according to at least one of Claims 1 to 11, wherein R<sup>6A</sup> is hydrogen.
  - 13. Compounds of general formula (I-B) according to at least one of Claims 1 to 11, wherein R<sup>6B</sup> is methyl, (1H-imidazol-2-yl)methyl, 2-(diethylamino)ethyl, 2-hydroxyethyl, 3-hydroxypropyl and 2-(1-pyrrolidinyl)ethyl.

## 14. Compounds of general formula (I-C)

$$R^{1}$$
 $R^{4}$ 
 $R^{4}$ 
 $R^{3}$ 
 $R^{3}$ 
 $CF_{3}$ 
 $(I-C)$ 

wherein

5

- Z represents CH or N, and R<sup>1</sup>, R<sup>3</sup> and R<sup>4</sup> have the meaning indicated in Claims 1 to 12.
- 15. Compounds of general formula (I-E)

10

$$R^{1}$$
 $R^{4}$ 
 $R^{4}$ 
 $R^{3}$ 
 $R^{3}$ 
 $CF_{3}$ 
 $(I-E)$ 

wherein

Z represents CH or N,

15

R<sup>1</sup>, R<sup>3</sup> and R<sup>4</sup> have the meaning indicated above, and

R<sup>6B</sup> represents C<sub>1</sub>-C<sub>4</sub>-alkyl, which can be substituted with a radical selected from the group consisting of hydroxy, di-C<sub>1</sub>-C<sub>4</sub>-alkylamino, phenyl, pyridyl, imidazolyl, pyrrolidino and morpholino.

5

16. Process for synthesizing the compounds of general formulas (I-A), (I-B), (I-C) or (I-E), respectively, as defined in Claims 1 to 15, by condensing compounds of general formula (II)

$$R^{1}$$
 $A$ 
 $CHO$ 
 $(II)$ ,

10

wherein A, R<sup>1</sup> and R<sup>2</sup> have the meaning indicated in Claims 1 to 15,

with compounds of general formula (III)

15

$$R^{4}$$
  $O$  (III),

wherein R<sup>4</sup> and R<sup>5</sup> have the meaning indicated in Claims 1 to 15,

20

and compounds of general formula (IV)

wherein R<sup>3</sup>, R<sup>7</sup>, and Y<sup>1</sup> to Y<sup>4</sup> have the meaning indicated in Claims 1 to 15,

in the presence of an acid either in a three-component / one-step reaction or sequentially to give compounds of the general formula (I-D)

$$R^{1}$$
 $A$ 
 $R^{4}$ 
 $A$ 
 $R^{5}$ 
 $N$ 
 $S$ 
 $Y_{1}^{1}$ 
 $Y_{2}^{4}$ 
 $Y_{3}^{1}$ 
 $X_{1}^{7}$ 
 $X_{2}^{7}$ 
 $X_{3}^{7}$ 
 $X_{4}^{7}$ 
 $X_{5}^{7}$ 

wherein

10

A, R<sup>1</sup> to R<sup>5</sup>, R<sup>7</sup>, and Y<sup>1</sup> to Y<sup>4</sup> have the meaning indicated in Claims 1 to 15, optionally followed by reaction of the compounds of general formula (I-D) in the presence of a base either

15

[A] with compounds of the general formula (V)

$$R^{6A*}-X^A$$
 (V)

wherein R<sup>6A\*</sup> has the meaning of R<sup>6A</sup> as indicated in Claims 1 to 15, but does not represent hydrogen, and X<sup>A</sup> represents a leaving group, such as halogen,

5

15

ززز

to give compounds of the general formula (I-A) or (I-C), respectively,

or

10 [B] with compounds of the general formula (VI)

$$R^{6B}-X^B$$
 (VI),

wherein R<sup>6B</sup> has the meaning indicated in Claims 1 to 15, and X<sup>B</sup> represents a leaving group, such as halogen, tosylate, mesylate or sulfate,

to give compounds of the general formula (I-B) or (I-E), respectively.

- 20 17. The composition containing at least one compound of general formula (I-A) or (I-C), as defined in Claims 1 to 12 and 14, and a pharmacologically acceptable diluent.
- 18. A composition according to Claim 17 for the treatment of acute and chronic inflammatory, ischaemic and/or remodelling processes.
  - 19. The process for the preparation of compositions according to Claim 17 and 18 characterized in that the compounds of general formula (I-A) or (I-C), as defined in Claims 1 to 12 and 14, together with customary auxiliaries are brought into a suitable application form.

- 20. Use of the compounds of general formula (I-A) or (I-C), as defined in Claims 1 to 12 and 14, for the preparation of medicaments.
- Use according to Claim 20 for the preparation of medicaments for the treatment of acute and chronic inflammatory, ischaemic and/or remodelling processes.
- 22. Use according to Claim 21, wherein the process is chronic obstructive pulmonary disease, acute coronary syndrome, acute myocardial infarction or development of heart failure.
  - 23. The composition containing at least one compound of general formula (I-B) or (I-E), as defined in Claims 1 to 11, 13 and 15, and a pharmacologically acceptable diluent.
  - 24. A composition according to Claim 23 for the treatment of acute and chronic inflammatory, ischaemic and/or remodelling processes.
- 25. The process for the preparation of compositions according to Claim 23 and 24 characterized in that the compounds of general formula (I-B) or (I-E), as defined in Claims 1 to 11, 13 and 15, together with customary auxiliaries are brought into a suitable application form.
- Use of the compounds of general formula (I-B) or (I-E), as defined in Claims

  1 to 11, 13 and 15, for the preparation of medicaments.
  - 27. Use according to Claim 26 for the preparation of medicaments for the treatment of acute and chronic inflammatory, ischaemic and/or remodelling processes.

- 28. Use according to Claim 27, wherein the process is chronic obstructive pulmonary disease, acute coronary syndrome, acute myocardial infarction or development of heart failure.
- Process for controlling chronic obstructive pulmonary disease, acute coronary syndrome, acute myocardial infarction or development of heart failure in humans and animals by administration of a neutrophil elastase inhibitory amount of at least one compound according to any of Claims 1 to 15.